Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Nisticò · SciRah

Researcher profile · Semantic Scholar

C. Nisticò

Share profile

C. Nisticò — researcher profile on SciRah

h-index: 26
Works: 123
Citations: 2,407

Most-cited papers

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
L. Del Mastro, S. De Placido, P. Bruzzi, M. de Laurentiis +20 more
2015The Lancet181 citations
Semantic Scholar
Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials
E. Bria, F. Cuppone, M. Fornier, C. Nisticò +6 more
2008Breast Cancer Research and Treatment166 citations
Semantic Scholar
Benefit of taxanes as adjuvant chemotherapy for early breast cancer
E. Bria, C. Nisticò, F. Cuppone, P. Carlini +6 more
2006Cancer158 citations Open access
Semantic Scholar
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer
F. Cuppone, E. Bria, S. Verma, K. Pritchard +7 more
2008Cancer122 citations
Semantic Scholar
A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study
F. Novelli, M. Milella, E. Melucci, A. di Benedetto +9 more
2008Breast Cancer Research113 citations Open access
Semantic Scholar
Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
P. Papaldo, Massimo Lopez, P. Marolla, E. Cortesi +15 more
2005Journal of Clinical Oncology103 citations Open access
Semantic Scholar
HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care
A. Fabi, A. di Benedetto, G. Metro, L. Perracchio +10 more
2011Clinical Cancer Research98 citations Open access
Semantic Scholar
Gemcitabine‐based combinations for inoperable pancreatic cancer: Have we made real progress?
E. Bria, M. Milella, A. Gelibter, F. Cuppone +7 more
2007Cancer87 citations Open access
Semantic Scholar
Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
P. Papaldo, Massimo Lopez, E. Cortesi, E. Cammilluzzi +16 more
2003Journal of Clinical Oncology79 citations
Semantic Scholar
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials
V. Rossi, P. Berchialla, D. Giannarelli, C. Nisticò +10 more
2019Cancers70 citations Open access
Semantic Scholar
Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.
E. Bria, F. Cuppone, M. Ciccarese, C. Nisticò +6 more
2006Cancer Treatment Reviews66 citations
Semantic Scholar
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer.
A. Fabi, D. Alesini, E. Valle, L. Moscetti +26 more
2018Breast53 citations
Semantic Scholar
Induction of ErbB-3 Expression by α6β4 Integrin Contributes to Tamoxifen Resistance in ERβ1-Negative Breast Carcinomas
V. Folgiero, Paolo Avetrani, G. Bon, S. D. Di Carlo +11 more
2008PLoS ONE51 citations Open access
Semantic Scholar
Taxanes as primary chemotherapy for early breast cancer
F. Cuppone, E. Bria, P. Carlini, M. Milella +6 more
2008Cancer50 citations
Semantic Scholar
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.
L. Del Mastro, F. Poggio, E. Blondeaux, S. De Placido +24 more
2022The Lancet Oncology48 citations
Semantic Scholar
Taxanes with anthracyclines as first‐line chemotherapy for metastatic breast carcinoma
E. Bria, D. Giannarelli, A. Felici, W. Peters +5 more
2005Cancer46 citations
Semantic Scholar
Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue?
A. Pace, C. Nisticò, F. Cuppone, E. Bria +8 more
2007Clinical Breast Cancer44 citations
Semantic Scholar
Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?
P. Papaldo, G. Ferretti, S. Di Cosimo, D. Giannarelli +16 more
2006Journal of Clinical Oncology41 citations Open access
Semantic Scholar
Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues
E. Bria, F. Cuppone, M. Milella, S. Verma +7 more
2008Expert Opinion on Biological Therapy37 citations
Semantic Scholar
Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials
F. Cuppone, E. Bria, V. Vaccaro, F. Puglisi +11 more
2011Journal of experimental & clinical cancer research : CR35 citations Open access
Semantic Scholar
Clinical Significance of PTEN and p-Akt Co-Expression in HER2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab-Based Therapies
A. Fabi, G. Metro, A. di Benedetto, C. Nisticò +8 more
2010Oncology33 citations
Semantic Scholar
New aromatase inhibitors as second‐line endocrine therapy in postmenopausal patients with metastatic breast carcinoma
P. Carlini, E. Bria, D. Giannarelli, G. Ferretti +10 more
2005Cancer30 citations Open access
Semantic Scholar
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?
A. Fabi, D. Giannarelli, L. Moscetti, D. Santini +15 more
2017Future Oncology28 citations
Semantic Scholar
Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: Meta-analysis of randomized trials
F. Cuppone, E. Bria, D. Giannarelli, V. Vaccaro +10 more
2010BMC Cancer25 citations Open access
Semantic Scholar
Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients
A. Fabi, D. Giannarelli, P. Malaguti, G. Ferretti +8 more
2015Drug Design, Development and Therapy23 citations Open access
Semantic Scholar
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
A. Fabi, M. Russillo, G. Ferretti, G. Metro +7 more
2012BMC Cancer20 citations Open access
Semantic Scholar
Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients.
E. Bria, M. Ciccarese, D. Giannarelli, F. Cuppone +7 more
2006Cancer Treatment Reviews20 citations
Semantic Scholar
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation.
L. Carbognin, I. Sperduti, A. Fabi, M. Dieci +19 more
2017Breast19 citations Open access
Semantic Scholar
p53 centrosomal localization diagnoses ataxia-telangiectasia homozygotes and heterozygotes.
A. Prodosmo, A. De Amicis, C. Nisticò, M. Gabriele +6 more
2013Journal of Clinical Investigation19 citations Open access
Semantic Scholar
Does adjuvant chemotherapy improve survival in non small cell lung cancer (NSCLC)? A pooled-analysis of 6494 patients in 12 studies, examining survival and magnitude of benefit
E. Bria, R. Gralla, H. Raftopoulos, G. Ferretti +6 more
200519 citations
Semantic Scholar
A Real‐World Multicentre Retrospective Study of Paclitaxel‐Bevacizumab and Maintenance Therapy as First‐Line for HER2‐Negative Metastatic Breast Cancer
T. Gamucci, L. Mentuccia, C. Natoli, I. Sperduti +27 more
2016Journal of Cellular Physiology18 citations Open access
Semantic Scholar
Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer
A. Fabi, R. Merola, G. Ferretti, A. di Benedetto +13 more
2013Expert Opinion on Pharmacotherapy16 citations
Semantic Scholar
Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin–paclitaxel in metastatic breast cancer patients
C. Nisticò, E. Bria, F. Cuppone, A. Carpino +8 more
2007Anti-Cancer Drugs16 citations
Semantic Scholar
Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
Matteo Allegretti, A. Fabi, E. Giordani, Cristiana Ercolani +10 more
2021Molecular Cancer15 citations Open access
Semantic Scholar
Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients.
A. Fabi, G. Ferretti, P. Malaguti, Simona Gasparro +8 more
2020Future Oncology13 citations
Semantic Scholar
Second-Degree Type 2 Atrioventricular Block Requiring Permanent Cardiac Pacing in Patients on CDK4/6 Inhibitors: Report of Two Cases
M. P. Cicini, G. Ferretti, N. Morace, C. Nisticò +2 more
2021Breast Care12 citations Open access
Semantic Scholar
Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial.
A. Fabi, I. Terrenato, A. Vidiri, V. Villani +14 more
2021Future Oncology11 citations Open access
Semantic Scholar
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.
B. Conte, M. Bruzzone, M. Lambertini, F. Poggio +17 more
2020European Journal of Cancer11 citations
Semantic Scholar
Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?
G. Ferretti, E. Bria, D. Giannarelli, P. Carlini +9 more
2005Journal of Clinical Oncology10 citations
Semantic Scholar
Primary chemotherapy with epirubicin and vinorelbine in women with locally advanced breast cancer.
C. Nisticò, A. de Matteis, E. Rossi, F. Carnino +12 more
2005Anticancer Research9 citations
Semantic Scholar
Weekly Docetaxel in Pretreated Metastatic Breast Cancer Patients: A Phase I-II Study
C. Nisticò, F. Cognetti, L. Frontini, S. Barni +8 more
2005Oncology9 citations
Semantic Scholar
Adjuvant Chemotherapy for Non-small Cell Lung Cancer
E. Bria, F. Cuppone, F. Cecere, M. Milella +3 more
2007Journal of Thoracic Oncology8 citations Open access
Semantic Scholar
Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study
C. Nisticò, E. Bria, F. Cuppone, M. Fornier +5 more
2007Anti-Cancer Drugs8 citations
Semantic Scholar
Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors
C. Nisticò, F. Cuppone, E. Bria, M. Fornier +6 more
2006Anti-Cancer Drugs8 citations
Semantic Scholar
134O Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)
L. Del Mastro, F. Poggio, E. Blondeaux, S. De Placido +14 more
2022Annals of Oncology6 citations Open access
Semantic Scholar
Should subgroup analysis of randomized clinical trials have a direct impact on clinical practice?
E. Bria, M. di Maio, F. Cuppone, C. Nisticò +2 more
2007Journal of Clinical Oncology6 citations Open access
Semantic Scholar
p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study.
A. Fabi, M. Mottolese, A. di Benedetto, F. Sperati +12 more
2020Clinical Breast Cancer5 citations
Semantic Scholar
Magnitude of risks and benefits of the addition of bevacizumab (BEVA) to chemotherapy (CT) for patients (pts) with advanced breast cancer (ABC): Metaregression analysis of randomized trials (RCT).
F. Cuppone, E. Bria, I. Sperduti, V. Vaccaro +6 more
20105 citations
Semantic Scholar
Aromatase inhibitors in post-menopausal metastatic breast carcinoma
P. Carlini, E. Bria, D. Giannarelli, A. Felici +14 more
2007Expert Opinion on Investigational Drugs5 citations
Semantic Scholar
O-120 Pooled-analysis of 6494 patients in 12 trials (1994–2004)receiving post-operative adjuvant chemotherapy in non-small cell lung cancer: Analyzing the magnitude of benefit in survival
E. Bria, R. Gralla, D. Giannarelli, H. Raftopoulos +6 more
20055 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

F. Cognetti×40
Invite
F. Cognetti — researcher profile on SciRah
D. Giannarelli×28
Invite
D. Giannarelli — researcher profile on SciRah
E. Bria×27
Invite
E. Bria — researcher profile on SciRah
A. Fabi×25
Invite
A. Fabi — researcher profile on SciRah

×24

Invite

E. Terzoli — researcher profile on SciRah

Invite

F. Cuppone — researcher profile on SciRah

G. Ferretti×21

Invite

G. Ferretti — researcher profile on SciRah

Invite

P. Carlini — researcher profile on SciRah

Invite

M. Milella — researcher profile on SciRah

I. Sperduti×15

Invite

I. Sperduti — researcher profile on SciRah

Invite

P. Papaldo — researcher profile on SciRah

M. Mottolese×10

Invite

M. Mottolese — researcher profile on SciRah